Search Results - "Menzen, Markus"

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes by Aberle, Jens, Menzen, Markus, Schmid, Sebastian M., Terkamp, Christoph, Jaeckel, Elmar, Rohwedder, Katja, Scheerer, Markus F., Xu, John, Tang, Weifeng, Birkenfeld, Andreas L.

“…Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have…”
Get full text

Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA by Molderings, Gerhard J, Zienkiewicz, Thomas, Homann, Jürgen, Menzen, Markus, Afrin, Lawrence B

“… It has been shown repeatedly that mast cells can promote or prevent cancer development and growth. If development and/or progression of a solid cancer is…”
Get full text

76-LB: Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)–Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting—SURE Program Post Hoc Analysis by RUDOFSKY, GOTTFRIED, MENZEN, MARKUS, POTIER, LOUIS, CATARIG, ANDREI-MIRCEA, CLARK, ALICE, PRIYADARSHINI, PRACHI, ABREU, CRISTINA

“…Retrospective database studies have shown that switching between some GLP-1RAs may be associated with additional benefits on glycemic control and body weight…”
Get full text

797-P: Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D by YALE, JEAN-FRANÇOIS, MAJOR-PEDERSEN, ATHELINE, CATARIG, ANDREI-MIRCEA, JAIN, RASHMI, MENZEN, MARKUS, HOLMES, PATRICK

“…Real-world (RW) drug safety studies complement safety information from randomized clinical trials. This post hoc analysis of pooled data from nine global…”
Get full text

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany by Menzen, Markus, Berentzen, Tina Landsvig, Catarig, Andrei-Mircea, Pieperhoff, Sebastian, Simon, Jörg, Jacob, Stephan

“…Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum…”
Get more information

Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme by Yale, Jean‐François, Major‐Pedersen, Atheline, Catarig, Andrei‐Mircea, Jain, Rashmi, Menzen, Markus, Holmes, Patrick

“…Aim To investigate, through post hoc analysis of nine studies from the SemaglUtide Real‐world Evidence (SURE) programme, the safety of once‐weekly (OW)…”
Get full text

Case report: Auditory neuropathy in systemic mast cell activation disease by Strenzke, Nicola, Menzen, Markus, Homann, Jürgen, Molderings, Gerhard J.

“…A 23-year-old female patient with severe familial systemic mast cell activation disease (MCAD) reported fluctuating hearing impairment and tinnitus which both…”
Get full text

It's a new world: Improvement of diabetes therapy through digital and technical innovations by Menzen, Markus

“…Medical progress is increasingly characterized by digital and technical solutions that improve and facilitate treatment of our patients. Especially diabetes…”
Get more information

Pharmacological treatment options for mast cell activation disease by Molderings, Gerhard J., Haenisch, Britta, Brettner, Stefan, Homann, Jürgen, Menzen, Markus, Dumoulin, Franz Ludwig, Panse, Jens, Butterfield, Joseph, Afrin, Lawrence B.

“…Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast…”
Get full text

Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing by Altmüller, Janine, Haenisch, Britta, Kawalia, Amit, Menzen, Markus, Nöthen, Markus M., Fier, Heide, Molderings, Gerhard J.

“…Mast cell activation syndrome (MCAS) and systemic mastocytosis (SM) are two clinical systemic mast cell activation disease variants. Few studies to date have…”
Get full text

Area-specific increased density of μ-opioid receptor immunoreactive neurons in the cerebral cortex of drug-related fatalities by Schmidt, Peter, Schmolke, Cordula, Musshoff, Frank, Menzen, Markus, Prohaska, Cathleen, Madea, Burkhard

“…In animal experiments and in cell culture, chronic morphine treatment has been followed by “up-regulation” as well as “down-regulation” of the μ-opioid…”
Get full text

Area-specific increased density of [mu]-opioid receptor immunoreactive neurons in the cerebral cortex of drug-related fatalities by Schmidt, Peter, Schmolke, Cordula, Musshoff, Frank, Menzen, Markus, Prohaska, Cathleen, Madea, Burkhard

“…In animal experiments and in cell culture, chronic morphine treatment has been followed by "up-regulation" as well as "down-regulation" of the μ-opioid…”
Get full text

Pharmaceutical care of a patient with acute diabetic foot syndrome by Kaufmann, Denise, Walkenbach, Katharina, Döhler, Nele, Wagemann, Georg, Menzen, Markus, Homann, Jürgen, Jaehde, Ulrich

Get more information

Pharmaceutical care of an osteoporosis patient with hypothyroidism by Heumüller, Rebekka, Kretschmer, Inga, Döhler, Nele, Wittich, Rüdiger, Menzen, Markus, Homann, Jürgen, Jaehde, Ulrich

Get more information